Genentech Inc.says U.S. physicians can order Lucentis (ranibizumab) at a 0.3 mg monthly dose for diabetic macular edema immediately and product will start shipping Aug. 15, following FDA’s Aug. 10 approval for this indication.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?